Neurogene Inc. 8K

Neurogene furnished an August 2026 corporate presentation outlining strong Phase 1/2 NGN-401 Rett syndrome data, completion of dosing in its Embolden registrational trial, and a path toward BLA submission with associated CMC and commercial-readiness milestones.

Neurogene Inc. furnished an August 2026 corporate presentation describing clinical progress and commercialization plans for NGN-401, its one-time intracerebroventricular AAV gene therapy for Rett syndrome, emphasizing that Phase 1/2 data in 10 participants show durable, multidomain developmental milestone gains with a generally well-tolerated 1E15 vg dose, that the Embolden registrational trial for females aged ≥3 years has completed dosing of 25 patients with topline results expected in the second half of 2027, and that the company is preparing for a Biologics License Application through completion of BLA-enabling CMC Process Performance Qualification runs by year-end 2026, supported by in-house AAV manufacturing, payer research, and early commercial-readiness activities aimed at a multi-billion-dollar rare disease market with no approved disease-modifying therapies.

Filing Facts

CIK

1404644

Ticker

NGNE

Form

8K

Source Type

fda

Accession

0001404644-26-000056

Alert Tier

6